N/A N=50 Bariatric Surgery for Morbid Obesity
Obesity · Morbid Obesity
Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=42 Teaching Obesity Treatment Options to Adult Learners Trial
Obesity · Patient Education · Weight Loss
Primary: Recruitment — 42 Participants
Phase 2 N=30 Topiramate in Adolescents With Severe Obesity
Obesity, Morbid · Obesity · Weight Loss
Primary: Percent Change From Baseline in Body Mass Index at 28-Weeks — -2.74; -0.85 % change BMI
N/A N=17 Lifestyle Program for Obstructive Sleep Apnea With Severe Obesity
Obstructive Sleep Apnea · Obesity
Primary: Ability to Use the Devices at Home — 15 Participants
N/A N=81 Effects of Different Surgical Methods to Treat Obesity
Obesity · Type 2 Diabetes · Insulin Sensitivity
Primary: Insulin Sensitivity at 2 Years — 6.7; 6.6 glucose/kg body weight/min
Phase 3 N=50 Safety and Efficacy of Adjustable Gastric Band Operations for Patients With Body Mass Index (BMI) Between 30-40 kg/m2
Obesity
Primary: To Determine Percent of Excess Weight Loss (%EWL) After Laparoscopic Adjustable Gastric Banding Surgery — 51.74 percentage of excess weight loss
Phase 2 N=474 A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
Obesity
Primary: Percent Change From Baseline in Body Weight at Week 26 — -1.76; -8.51; -9.83; -11.80 Percent Change — p=< 0.001
N/A N=88 Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes
Type 2 Diabetes Mellitus · Obesity
Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60
Phase 2 N=26 Exenatide in Extreme Pediatric Obesity
Obesity
Primary: Percent Change From Baseline in Body Mass Index at 3-months — -2.9; -0.15 percentage of change in BMI
Phase 4 N=144 Surgical Conditions During Laparoscopic Bariatric Surgery
Morbid Obesity
Primary: Surgeon Satisfaction Scale — 2.7; 4.1; 3.1; 4.6 Scores on a scale
N/A N=150 Gastric Procedures for Obesity
Morbid Obesity
Primary: Change in Body Weight — -21.4; -36.6; -7.0 kg
N/A N=28 Increased Monitoring of Physical Activity and Calories With Technology
Weight Change, Body · Behavior, Health · Obesity, Childhood
Primary: BMI Percentile — 98.46; 99.37 BMI percentile for age and sex
N/A N=24 Endoscopic Surgery for Bariatric Revision After Weight Loss Failure
Morbid Obesity · Weight Loss
Primary: Mean Weight Loss — 13.3 Pounds
N/A N=3 Deep Brain Stimulation Effects on Weight Change and Metabolic Rate
Obesity
Primary: Change in Metabolic Rate — 7.6; 18 percentage of increase in REM and SEE
Phase 2 N=49 Oxidative Stress in Asthma
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
N/A N=281 Maternal-Offspring Metabolics:Family Intervention Trial
Pregnancy · Weight Gain
Primary: Gestational Weight Gain (GWG) — 12; 10 kg — p=0.01
Phase 2 N=150 SMART Use of Medication for the Treatment of Adolescent Severe Obesity
Adolescent Obesity
Primary: Percent Change in Body Mass Index (BMI) — -9.62; -12.27; -4.53; -2.53 % change in body mass index (BMI)
N/A N=126 Weight Loss With Meal-Replacement Therapy in Teens
Obesity, Severe · Pediatric Obesity
Primary: Body Mass Index (From Baseline to 1-year) — -0.9; -6.6 Percent change in BMI
Phase 2 N=65 Qsymia as an Adjunct to Surgical Therapy in the Superobese
Obesity · Metabolic Surgery · Weight Loss
Primary: Proportion of Patients Who do Not Meet the Criteria to Move Forward With Roux en Y Gastric Bypass (RYGB) — 8; 19 Participants
Phase 1 N=22 PED NEONAT 20-000599 Fetal Body Composition
IUGR · Gestational Diabetes · Pregnancy Related
Primary: Maternal Visceral Adipose Tissue Volume — 97593; 169626; 96787 mm3
Phase 4 N=15 Levofloxacin Pharmacokinetics (PK) in the Severely Obese
Obesity · Critical Illness
Primary: Plasma Concentration of Levofloxacin — 76 mg/L*hr
Phase 3 N=1,267 Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults
Obesity
Primary: Percent Weight Loss From Baseline to Week 56 — 1.55; 5.10; 10.92 percent weight loss — p=<0.0001
N/A N=600 Clinical Staging Tools for the Impacts of Obesity on Individuals
Morbid Obesity
Primary: Changes in Obesity Scores After Weight Loss Treatment — 600 Participants
N/A N=264 Preventing Excessive Gestational Weight Gain in Obese Women
Obesity
Primary: Weight Gain Per Week of Observation — 0.39; 0.33 kg/wk
N/A N=48 Evaluation of EndoZip System in Obese Patients Who Failed to Reduce Weight With Non-surgical Weight-loss Methods
Obesity
Primary: Change in Body Total Body Weight Loss (kg) From Baseline to12 Months — 13.2 kg
N/A N=47 Healthy Bodies, Healthy Kids
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
N/A N=5,392 Impact of Body Weight on the Immediate Health of the Pediatric Population
Childhood Obesity
Primary: Diagnosis of Infectious Disease — 900; 1067 Participants — p=.026
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
N/A N=137 LAGB as a Treatment for Morbid Obesity in Adolescents
Morbid Obesity · Obstructive Sleep Apnea Syndrome · Metabolic Syndrome
Primary: Percentage of Excess Weight Change (EWL) — -35.5 percent change
N/A N=11,545 Bariatric Surgery and COVID-19
COVID-19 · Bariatric Surgery Candidate
Primary: Revisions — 746; 316 Participants